Biogen BIIB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $319.5M+32.8% | $0-100% | $466.5M+20.1% | $634.8M+8.8% | $240.5M-38.9% | ||
| $204.4M+11.6% | $200.2M+8.8% | $202.2M+10.6% | $194.3M+22.3% | $183.2M+24.2% | ||
| $84M+3.7% | $59.6M-20.6% | $75.3M+3.6% | $74.9M+6.1% | $81M+11.3% | ||
| $23.6M+185% | $166.9M+386% | $253.8M+583% | -$31.3M+64.0% | -$27.8M-170% | ||
| —— | -$25.68M+53.8% | -$25.68M+53.8% | -$25.68M+53.8% | -$25.68M+53.8% | ||
| -$116.2M-87.4% | $29.4M-55.7% | $7.4M-61.5% | $89.9M-18.6% | -$62M-180% | ||
| -$243.2M+19.1% | $203.8M+87.3% | $286M— | -$18.2M— | -$300.5M-69.7% | ||
| —— | -$62M-38.8% | -$62M-38.8% | -$62M-38.8% | -$62M-38.8% | ||
| $89M+66.4% | —— | $104.4M— | $22M-53.1% | $53.5M-4.6% | ||
| $18.4M-73.4% | -$194M-1,283% | -$229.4M-429% | -$603.8M-10,878% | $69.1M+3,241% | ||
| $19M+146% | —— | -$500K— | —— | -$40.9M-30.7% | ||
| $20.5M+114% | —— | $5.6M-76.5% | $13.2M— | $9.6M— | ||
| $645.5M+149% | $511.9M-32.7% | $1.27B+36.0% | $160.9M-74.3% | $259.3M-53.1% | ||
| $51.2M+38.0% | $43.9M+11.7% | $46.2M+32.0% | $26.6M-20.6% | $37.1M-19.2% | ||
| $748.8M— | $1.17B— | —— | —— | $0— | ||
| $500K— | —— | $56.6M+44.4% | $0-100% | $0-100% | ||
| $0-100% | $16.3M-39.6% | $5.3M-94.4% | $0-100% | $10M-86.7% | ||
| $200K0.0% | -$22.7M-7,667% | -$50.8M-4,718% | $30.4M+1,069% | $200K-71.4% | ||
| $35M— | —— | —— | —— | $0— | ||
| -$209.5M-343% | -$1.23B-6,522% | -$35.1M+97.0% | -$57M-112% | -$47.3M+28.3% | ||
| $55.1M+127% | —— | —— | —— | $24.3M-48.2% | ||
| $11.3M+769% | $138.7M— | $141.2M+2,453% | $0+100% | $1.3M-82.2% | ||
| -$43.8M-90.4% | -$137M— | -$130.2M-1,873% | -$11.7M+95.2% | -$23M+94.8% | ||
| -$18M-152% | $2.5M+103% | $0-100% | $68.3M+642% | $34.3M+248% | ||
| $392.2M+108% | —— | $1.11B— | $92.2M-89.1% | $189M+297% | ||
| $107.6M+109% | $75.4M+67.9% | $61.5M+20.8% | $52.5M-41.7% | $51.4M+16.6% | ||
| $20.5M+114% | —— | $5.6M-76.5% | $13.2M— | $9.6M— | ||
| $4.8M-34.2% | $15.3M-53.9% | $0-100% | $7M-58.6% | $7.3M-73.5% | ||
| —— | $13.23M— | $13.23M— | $13.23M— | $13.23M— | ||
| -$28M-318% | -$19M+70.5% | -$33.3M-10.6% | -$9.3M+76.5% | -$6.7M+73.6% | ||
| —— | $21.25M— | $21.25M— | $21.25M— | $21.25M— | ||
| $200K0.0% | -$22.7M-7,667% | -$50.8M-4,718% | $30.4M+1,069% | $200K-71.4% | ||
| $35M— | —— | —— | —— | $0— | ||
| $0-100% | $16.3M-39.6% | $5.3M-94.4% | $0-100% | $10M-86.7% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $11.3M+769% | —— | $6.2M+149% | —— | $1.3M-82.2% | ||
| $594.3M+167% | $468M-35.1% | $1.23B+36.2% | $134.3M-77.3% | $222.2M-56.2% | ||
| $594.3M+167% | $468M-35.1% | $1.23B+36.2% | $134.3M-77.3% | $222.2M-56.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Biogen generate?
- Biogen (BIIB) generated $2.6B in operating cash flow over the trailing twelve months.
- What is Biogen's free cash flow?
- After $167.9M of capital expenditures, Biogen's free cash flow was $2.4B over the trailing twelve months, down 0.6% year over year.
- Where does Biogen's cash flow data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
